Sen. Markwayne Mullin Buys Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of Intuitive Surgical, Inc. (NASDAQ:ISRG). In a filing disclosed on January 16th, the Senator disclosed that they had bought between $15,001 and $50,000 in Intuitive Surgical stock on December 29th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Deere & Company (NYSE:DE) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Hilton Worldwide (NYSE:HLT) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of CocaCola (NYSE:KO) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 12/29/2025.
• Purchased $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/29/2025.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Boston Scientific (NYSE:BSX) on 12/29/2025.

Intuitive Surgical Stock Down 1.2%

Shares of NASDAQ:ISRG opened at $535.00 on Monday. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The stock has a market cap of $191.79 billion, a P/E ratio of 70.77, a PEG ratio of 4.35 and a beta of 1.67. The business has a fifty day moving average of $566.32 and a two-hundred day moving average of $511.86.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the previous year, the company posted $1.84 EPS. The company’s revenue was up 22.9% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 750 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total value of $435,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 464 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the transaction, the senior vice president owned 131 shares of the company’s stock, valued at approximately $71,852.19. This trade represents a 77.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 114,007 shares of company stock worth $63,533,844 over the last 90 days. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ISRG shares. BTIG Research reiterated a “buy” rating and issued a $616.00 target price (up from $589.00) on shares of Intuitive Surgical in a report on Wednesday, January 7th. Truist Financial lifted their price target on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Raymond James Financial set a $603.00 price objective on Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Argus increased their price objective on Intuitive Surgical from $600.00 to $630.00 in a research report on Monday, October 27th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $622.17.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Phase‑3 update on IS‑001 imaging drug — Intuitive advanced its Phase‑3 study aimed at reducing ureter injuries in robotic colorectal surgery, a safety-focused adjoint that could expand the company’s addressable offering and reinforce surgical‑safety differentiation. Intuitive Surgical Advances Phase 3 Imaging Drug
• Positive Sentiment: daVinci systems demand highlighted — Company commentary and industry coverage say system performance “exceeded expectations” and Intuitive is pushing for more placements, supporting procedure growth and recurring consumable revenue. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Positive Sentiment: Analyst support remains — At least some brokers (e.g., Bernstein) have reiterated buy ratings, signaling continued sell‑side conviction in ISRG’s long‑term growth profile despite near‑term noise. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Investor take: “buying the dip” narratives are emerging — Several bullish commentaries argue the pullback is an entry point given Intuitive’s wide moat, recurring consumables and procedure tailwinds. Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
• Neutral Sentiment: Analysts preparing for Q4 — Preview pieces outline the metrics (procedures, system placements, ASPs, margin drivers) that will matter when full Q4 results and guidance details arrive; these previews can amplify volatility around the print. Intuitive Surgical (ISRG) Q4 Earnings on the Horizon
• Neutral Sentiment: Brokerage commentary roundup — Coverage pieces remind investors that analyst ratings and model changes often move shares; they’re useful context but not a definitive signal by themselves. Brokers Suggest Investing in Intuitive Surgical (ISRG)
• Negative Sentiment: Preliminary Q4 revenue reaction — Although Intuitive reported strong preliminary Q4 and full‑year revenue growth, shares dipped as investors parsed procedure trends, margin dynamics and what management said about demand cadence. That disconnect between a beat and stock action is a key reason for the pullback. Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
• Negative Sentiment: Softer 2026 outlook flagged — Company commentary and reporting point to a softer 2026 outlook that trimmed forward expectations, which is the primary negative driver behind today’s weakness. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction analysis — Coverage asking “why did shares dive?” notes investors punished the stock for guidance/trajectory concerns despite the beat, illustrating that forward commentary and margin clarity matter more than one‑time beats. Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive?

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ISRG. Evexia Wealth LLC acquired a new position in Intuitive Surgical during the 4th quarter worth about $248,000. Omnia Family Wealth LLC purchased a new stake in Intuitive Surgical during the fourth quarter worth about $233,000. Beaumont Financial Advisors LLC lifted its position in shares of Intuitive Surgical by 6.4% during the fourth quarter. Beaumont Financial Advisors LLC now owns 650 shares of the medical equipment provider’s stock worth $368,000 after purchasing an additional 39 shares in the last quarter. Worth Financial Advisory Group LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $211,000. Finally, Earned Wealth Advisors LLC grew its holdings in shares of Intuitive Surgical by 19.1% in the fourth quarter. Earned Wealth Advisors LLC now owns 686 shares of the medical equipment provider’s stock valued at $389,000 after purchasing an additional 110 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.